secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001628280-26-030522
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum reports Q1 net loss $14.5M; cash $246.3M through mid-2029
-------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $246.3M as of March 31, 2026; runway through mid-2029.
- Net loss of $14.5M vs $16.0M in Q1 2025; R&D expenses down 15% to $11.6M.
- Positive topline Phase 1b data for PIPE-791 in chronic pain (April 30, 2026); safety met and numeric pain improvement.
- Initiated global Phase 2 PROPEL-IPF trial for PIPE-791 in IPF; target 324 patients; enrollment ongoing.
- Johnson & Johnson Phase 2 Moonlight-1 trial of PIPE-307 in MDD recruiting 124 participants; completion expected June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000162828026030522/0001628280-26-030522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000162828026030522/ctnm-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-030522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer